We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA again rejected a long-acting injectable formulation of Eli Lilly’s Zyprexa and asked the company to establish a risk evaluation and mitigation strategy (REMS) for the drug, the company told WDL.